81529-60-4

Basic information

• Product Name: 4-(2,4,6-TRIMETHYL-PHENYL)-THIAZOL-2-YLAMINE
• Synonyms: IFLAB-BB F1386-0353;4-(2,4,6-TRIMETHYL-PHENYL)-THIAZOL-2-YLAMINE;4-MESITYL-1,3-THIAZOL-2-AMINE;4-mesitylthiazol-2-amine
• CAS NO: 81529-60-4
• Molecular Formula: C₁₂H₁₄N₂S
• Molecular Weight: 218.32
• Mol File: 81529-60-4.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 351.4°Cat760mmHg
• Flash Point: 166.3°C
• Appearance: /
• Density: 1.158g/cm³
• Vapor Pressure: 4.11E-05mmHg at 25°C
• Refractive Index: 1.617
• CAS DataBase Reference: 4-(2,4,6-TRIMETHYL-PHENYL)-THIAZOL-2-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2,4,6-TRIMETHYL-PHENYL)-THIAZOL-2-YLAMINE(81529-60-4)
• EPA Substance Registry System: 4-(2,4,6-TRIMETHYL-PHENYL)-THIAZOL-2-YLAMINE(81529-60-4)

Safety Data

• Hazardous Substances Data: 81529-60-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C12H14N2S/c1-7-4-8(2)11(9(3)5-7)10-6-15-12(13)14-10/h4-6H,1-3H3,(H2,13,14)

Upstream product

• 1667-01-2 2,4,6-Trimethylacetophenone 
• 108-67-8 1,3,5-trimethyl-benzene 
• 4225-92-7 2-bromo-1-(2,4,6-trimethylphenyl)ethanone 
• 17356-08-0 thiourea 
• 50690-12-5 2-chloro-1-(2,4,6-trimethyl-phenyl)-ethanone 

Downstream Products

• 81529-83-1 2-Ethoxyethyl N-[4-(2,4,6-trimethylphenyl)-thiazol-2-yl]-oxamate 
• 1134986-18-7 thiazole-2-carboxylic acid [4-(2,4,6-trimethylphenyl)thiazol-2-yl]amide 
• 745022-89-3 pyrazine-2-carboxylic acid [4-(2,4,6-trimethylphenyl)thiazol-2-yl]amide 
• 1134986-24-5 morpholine-4-carboxylic acid [4-(2,4,6-trimethylphenyl)thiazol-2-yl]amide 
• 950032-53-8 pyridine-2-carboxylic acid [4-(2,4,6-trimethylphenyl)thiazol-2-yl]amide 
• 950078-55-4 N-[4-(2,4,6-trimethylphenyl)thiazol-2-yl]nicotinamide 
• 1001753-24-7 N-[4-(2,4,6-trimethylphenyl)-2-thiazolyl]-benzamide 
• 1134985-98-0 2-methoxy-N-[4-(2,4,6-trimethylphenyl)thiazol-2-yl]benzamide 
• 872456-21-8 2-trifluoromethyl-N-[4-(2,4,6-trimethylphenyl)thiazol-2-yl]benzamide 
• 849513-58-2 N-(4-mesitylthiazol-2-yl)isonicotinamide 
• 1334921-00-4 N-(4-mesitylthiazol-2-yl)-2-(pyridin-4-yl)acetamide 
• 313252-23-2 4-cyano-N-(4-mesitylthiazol-2-yl)benzamide 
• 1334920-60-3 4-[(4-mesitylthiazol-2-yl)carbamoyl]pyridine 1-oxide 
• 313366-31-3 4-[(4-mesitylthiazol-2-yl)carbamoyl]pyridine 1-oxide 

Relevant articles and documents

Identification of novel 2-aminothiazole conjugated nitrofuran as antitubercular and antibacterial agents

The emergence of antibiotic resistant pathogens is an ongoing main problem in the therapy of bacterial infections. In order to develop promising antitubercular and antibacterial lead compounds, we designed and synthesized a new series of derivatives of 2-aminothiazole conjugated nitrofuran with activities against both Mycobacterium tuberculosis and Staphylococcus aureus. Eight compounds 12e, 12k, 12l, 12m, 18a, 18d, 18e, and 18j emerged as promising antitubercular agents. Structure–activity relationships (SARs) were discussed and showed that the derivatives substituted at the position-3 of benzene of 5-nitro-N-(4-phenylthiazol-2-yl)furan-2-carboxamide exhibited superior potency. The most potent compound 18e, substituted with benzamide at this position, displayed minimum inhibitory concentrations (MICs) of 0.27 μg/mL against Mtb H37Ra and 1.36 μg/mL against S. aureus. Furthermore, compound 18e had no obvious cytotoxicity to normal Vero cells (IC50= 50.2 μM). The results suggest that the novel scaffolds of aminothiazole conjugated nitrofuran would be a promising class of potent antitubercular and antimicrobial agents.

Discovery of 4-aryl-N-arylcarbonyl-2-aminothiazoles as Hec1/Nek2 inhibitors. Part I: Optimization of in vitro potencies and pharmacokinetic properties

A series of 4-aryl-N-arylcarbonyl-2-aminothiazoles of scaffold 4 was designed and synthesized as Hec1/Nek2 inhibitors. Structural optimization of 4 led to compound 32 bearing C-4′ 4-methoxyphenoxy and 4-(o-fluoropyridyl) carbonyl groups that showed low nanomolar in vitro antiproliferative activity (IC50: 16.3-42.7 nM), high intravenous AUC (64.9 μM·h, 2.0 mg/kg) in SD rats, and significant in vivo antitumor activity (T/C = 32%, 20 mg/kg, IV) in mice bearing human MDA-MB-231 xenografts. Cell responses resulting from Hec1/Nek2 inhibition were observed in cells treated with 32, including a reduced level of Hec1 coimmunoprecipitated with Nek2, degradation of Nek2, mitotic abnormalities, and apoptosis. Compound 32 showed selectivity toward cancer cells over normal phenotype cells and was inactive in a [ 3H]astemizole competitive binding assay for hERG liability screening. Therefore, 32 is as a good lead toward the discovery of a preclinical candidate targeting Hec1/Nek2 interaction.

Modulators Of HEC1 Activity And Methods Therefor

Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Especially preferred compounds disrupt Nek2/Hec1 binding and are therefore useful as chemotherapeutic agent for neoplastic diseases.